H-LSGRSDNH-OH

Ref. 3D-PP48692

Produktinformation

• Name: H-LSGRSDNH-OH

Beschreibung

Peptide H-LSGRSDNH-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-LSGRSDNH-OH include the following: Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency Y Yang, Q Guo, M Xia, Y Li, X Peng, T Liu, X Tong, J Xu - MAbs, 2015 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/19420862.2015.1008352 Ab locks for improving the selectivity and safety of antibody drugs WW Lin, YC Lu, CH Chuang, TL Cheng - Journal of Biomedical Science, 2020 - Springerhttps://link.springer.com/article/10.1186/s12929-020-00652-z an der, Gram W Wulp - M., Blei le ens, B., Hagedoorn, RS , 2023 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3656822/download Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells W van der Wulp, AM Gram, B Bleijlevens - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1183914/full Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes O Vasiljeva , E Menendez, M Nguyen, CS Craik - Scientific reports, 2020 - nature.comhttps://www.nature.com/articles/s41598-020-62339-7 Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody M Geiger, KG Stubenrauch, J Sam, WF Richter - Nature , 2020 - nature.comhttps://www.nature.com/articles/s41467-020-16838-w/1000 In vivo imaging of protease activity by Probody therapeutic activation KR Wong, E Menendez, CS Craik , WM Kavanaugh - Biochimie, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0300908415003508 Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastoma J Wang, S Toregrosa-Allen, BD Elzey , S Utturkar - BioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.10.07.330043.abstract Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity CD Leitao , AM Borras , T Xu, M Oroujeni, Y Liu - Journal of Controlled , 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168365923002298 Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity CCS Pai, DM Simons, X Lu, M Evans - The Journal of , 2019 - Am Soc Clin Investighttps://www.jci.org/articles/view/123391 Development of an Affibody-based Prodrug Against HER2 for Cancer Therapy C Westerberg - 2021 - diva-portal.orghttps://www.diva-portal.org/smash/record.jsf?pid=diva2:1595502 Novel ex vivo zymography approach for assessment of protease activity in tissues with activatable antibodies B Howng, MB Winter , C LePage, I Popova, M Krimm - Pharmaceutics, 2021 - mdpi.comhttps://www.mdpi.com/1999-4923/13/9/1390 Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker A Mansurov , P Hosseinchi , K Chang - Nature Biomedical , 2022 - nature.comhttps://www.nature.com/articles/s41551-022-00888-0

• Marke: Biosynth